NCT03642067

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

Phase A Phase 2 Study Evaluating Response and Biomarkers in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Treated With Nivolumab in Combination With Relatlimab

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS) colorectal cancer.

Conditions

• Microsatellite Stable (MSS) Colorectal Adenocarcinomas
• Colorectal Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Nivolumab	Nivolumab was administered IV on day 1 of each 28 day cycle.
DRUG	Relatlimab	Relatlimab was administered IV on day 1 of each 28 day cycle.

Timeline

• Start date: 2019-02-12
• Primary completion: 2024-02-23
• Completion: 2024-09-18
• First posted: 2018-08-22
• Last updated: 2025-06-15
• Results posted: 2025-01-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study